Dose-Escalation Trial Evaluating CPI-818

Brief Summary:

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.



Corvus Pharmaceuticals, Inc.

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03952078

Contact: Director Clinical Operations 650-900-4548


Participating Locations:

University of Pittsburgh Medical Center
Pittsburgh, PA, United States
Anahita Mohammady